This company has been marked as potentially delisted and may not be actively trading. Positive News SentimentPositive NewsNASDAQ:INTS Intensity Therapeutics, Inc. Common stock (INTS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrendsBuy This Stock About Intensity Therapeutics, Inc. Common stock Stock (NASDAQ:INTS) 30 days 90 days 365 days Advanced Chart Get INTS alerts:Sign Up Key Stats Today's Range$2.36▼$2.7950-Day Range N/A52-Week Range$0.32▼$5.10Volume73,559 shsAverage Volume60,159 shsMarket Capitalization$5.42 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingModerate Buy Company OverviewIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Read More… Intensity Therapeutics, Inc. Common stock Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreINTS MarketRank™: Intensity Therapeutics, Inc. Common stock scored higher than 40% of companies evaluated by MarketBeat, and ranked 666th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingIntensity Therapeutics, Inc. Common stock has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIntensity Therapeutics, Inc. Common stock has only been the subject of 1 research reports in the past 90 days.Read more about Intensity Therapeutics, Inc. Common stock's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intensity Therapeutics, Inc. Common stock are expected to grow in the coming year, from ($1.18) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intensity Therapeutics, Inc. Common stock is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intensity Therapeutics, Inc. Common stock is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntensity Therapeutics, Inc. Common stock has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.74% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics, Inc. Common stock has recently increased by 321.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntensity Therapeutics, Inc. Common stock does not currently pay a dividend.Dividend GrowthIntensity Therapeutics, Inc. Common stock does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.74% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics, Inc. Common stock has recently increased by 321.20%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 3 people have searched for INTS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows1 people have added Intensity Therapeutics, Inc. Common stock to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Intensity Therapeutics, Inc. Common stock insiders have not sold or bought any company stock.Percentage Held by Insiders18.60% of the stock of Intensity Therapeutics, Inc. Common stock is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.74% of the stock of Intensity Therapeutics, Inc. Common stock is held by institutions.Read more about Intensity Therapeutics, Inc. Common stock's insider trading history. Receive INTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intensity Therapeutics, Inc. Common stock and its competitors with MarketBeat's FREE daily newsletter. Email Address INTS Stock News HeadlinesIntensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | prnewswire.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in FranceMay 6, 2025 | prnewswire.comJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.May 22, 2025 | Premier Gold Co (Ad)Intensity Therapeutics announces $2.35M public offeringApril 26, 2025 | markets.businessinsider.comIntensity Therapeutics, Inc. Announces $2.35 Million Public OfferingApril 25, 2025 | prnewswire.comIntensity Therapeutics files to sell 4.26M shares of common stockApril 23, 2025 | markets.businessinsider.comIntensity Therapeutics Inc.: Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate UpdateMarch 15, 2025 | finanznachrichten.deIntensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate UpdateMarch 13, 2025 | prnewswire.comSee More Headlines INTS Stock Analysis - Frequently Asked Questions How were Intensity Therapeutics, Inc. Common stock's earnings last quarter? Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) issued its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.01. When did Intensity Therapeutics, Inc. Common stock IPO? Intensity Therapeutics, Inc. Common stock (INTS) raised $20 million in an initial public offering (IPO) on Friday, June 30th 2023. The company issued 3,900,000 shares at a price of $5.00 per share. Who are Intensity Therapeutics, Inc. Common stock's major shareholders? Top institutional shareholders of Intensity Therapeutics, Inc. Common stock include Sapient Capital LLC (6.47%), Armistice Capital LLC (5.78%) and Mesirow Financial Investment Management Inc. (0.26%). What other stocks do shareholders of Intensity Therapeutics, Inc. Common stock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics, Inc. Common stock investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ). Company Calendar Last Earnings5/13/2025Today5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INTS CIK1567264 Webwww.intensitytherapeutics.com Phone203 221 7381FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,136.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-209.73% Return on Assets-149.19% Debt Debt-to-Equity Ratio0.04 Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.96 per share Price / Book0.40Miscellaneous Outstanding Shares15,100,000Free Float12,295,000Market Cap$5.74 million OptionableNot Optionable Beta4.03 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:INTS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics, Inc. Common stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.